The Cigna Group (CI)

The Cigna Group is trading near the upper part of its 52-week range after a steady climb, but its latest earnings reaction was negative. The stock closed at $301.45, down 0.55% in the last session, and sits 5.22% below its 52-week high of $318.05. The November 5, 2026 report beat the EPS estimate by 6.26%, yet the shares fell 2.62% in the first session after the release. Across the five most recent reports, adjusted EPS beat the estimate every time and missed none, yet the share price fell in the first session after four of them and rose after only one. That pattern is the main tension investors are weighing against a trend that remains firmly up, with the price 5.01% above its 50-day SMA and 6.68% above its 200-day SMA.

The Cigna Group reported adjusted EPS of $7.98 on November 5, 2026, against an analyst estimate of $7.51, a beat of 6.26%. The shares nonetheless fell 2.62% in the first session after the report. This is not an isolated reaction. Across the five most recent reports, EPS beat the estimate every time, yet the stock moved lower in the first session after four of them. The only higher close came after the February 5, 2026 report, when the shares rose 2.64%. For an investor, this pattern means the earnings figure alone has not been the driver of the share price, and the market appears to be focused on other aspects of the outlook.

Despite the post-earnings declines, the price is 5.01% above its 50-day SMA and 6.68% above its 200-day SMA, and the 50-day SMA is 1.59% above the 200-day SMA. Over the past year the stock has risen 12.48%, and over six months the gain is a more modest 0.25%. The one-month return of 6.39% shows that the recent recovery has come from the lower part of the range. The stock is currently 72% of the way up its 52-week range, which places it closer to the high than the low.

The trailing P/E ratio of 13.29, a 58.3% discount to the sector median of 31.9. The price-to-sales ratio of 0.28 compares with a sector median of 3.4. Return on equity of 15.65% is above the sector median of 7.3%, although the net profit margin is only 2.09%. Of the 25 analysts with a current rating, 17 rate the stock buy or strong buy and 8 rate it hold, with none rating it sell. The median 12-month target of $340.00 is 12.8% above the price.

The base case is that the trend holds while earnings keep beating expectations and the analysts' forecasts for growth are met. Analysts expect earnings per share to rise 2.5% this fiscal year and 9.2% next year, and revenue to grow 4.6% this year. The median 12-month target of $340.00 sits 12.8% above the price, and the range runs from $288.00 to $400.00. Upside depends on the stock clearing the $318.05 high on steady results. Downside pressure would return if the price loses the 20-day EMA at $297.20 and the 50-day SMA at $287.06, or if beats continue to be met with selling. Analyst ratings are unlikely to move quickly, since all 25 current ratings are either buy or hold, with no sells.

Nearest support is the 20-day EMA at $297.20, which the price has recently held above. Next is the 50-day SMA at $287.06, followed closely by the 200-day SMA at $282.57, which sit near each other and together form a broader support zone. The 52-week low at $257.85 is the deepest level below the price. On the upside, the nearest resistance is the 52-week high at $318.05. A move above that level would mark a new high for the past year.